Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries for ion channels.


 

Fig. 1. The screening workflow of Receptor.AI

It includes extensive molecular simulations of the channel in its native membrane environment in open, closed and inactivated forms and the ensemble virtual screening accounting for conformational mobility in each of these states. Tentative binding pockets are considered inside the pore, in the gating region and in the allosteric locations to cover the whole spectrum of possible mechanisms of action.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P48544

UPID:
KCNJ5_HUMAN

ALTERNATIVE NAMES:
Cardiac inward rectifier; Heart KATP channel; Inward rectifier K(+) channel Kir3.4; KATP-1; Potassium channel, inwardly rectifying subfamily J member 5

ALTERNATIVE UPACC:
P48544; B2R744; Q6DK13; Q6DK14; Q92807

BACKGROUND:
The G protein-activated inward rectifier potassium channel 4, also known as Heart KATP channel or Kir3.4, plays a crucial role in maintaining potassium ion balance across the cardiac cell membrane. Its function is essential for the heart's electrical stability, regulated by G proteins and extracellular potassium levels.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of G protein-activated inward rectifier potassium channel 4 could open doors to potential therapeutic strategies for treating arrhythmias and hypertension, given its involvement in Long QT syndrome 13 and familial Hyperaldosteronism 3.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.